ESPR Q3 2025 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$87M+69.1% YoY

Gross Profit

$32M36.5% margin

Operating Income

-$10M-11.4% margin

Net Income

-$31M-35.9% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$364M

Total Liabilities

$815M

Stockholders' Equity

-$451M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$52M	+69.1%
Gross Profit	$32M	$34M	-7.2%
Operating Income	-$10M	-$16M	+37.9%
Net Income	-$31M	-$30M	-6.1%

Revenue Segments

Collaboration Revenue

$47M53%

Product

$41M47%